Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges

Recently, the development of antiangiogenic drugs has changed the therapy for metastatic renal cell carcinoma (RCC). As a result, the survival of individuals with advanced RCC has more than doubled. The median overall survival improved from 12 months during the cytokines era to near 30 months with a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights: Urology 2018-01, Vol.11
Main Authors: Aguiar, Pedro, Costa de Pádua, Tiago, Noia Barreto, Carmelia Maria, del Giglio, Auro
Format: Article
Language:English
Subjects:
Authorship
Cancer therapies
Clinical trials
Cytokines
Drug dosages
Drugs
FDA approval
Immunotherapy
Interferon
Kidney cancer
Metastasis
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, the development of antiangiogenic drugs has changed the therapy for metastatic renal cell carcinoma (RCC). As a result, the survival of individuals with advanced RCC has more than doubled. The median overall survival improved from 12 months during the cytokines era to near 30 months with antiangiogenic drugs. In this decade, the advent of immune checkpoint inhibitors showed enthusiastic results and is the new standard of care for patients with metastatic RCC previously treated with antiangiogenic drugs. The combination of immune checkpoint inhibitors plus antiangiogenic drugs may have a synergistic activity. As a result, current studies investigate the combination for treatment-naïve patients. This may potentially change clinical practice. In this article, we will highlight new therapeutic options available and agents or combinations that are being investigated for metastatic RCC.
ISSN:1179-5611
1179-5611
DOI:10.1177/1179561118765758